Sign In
Buy PRTK
$2.23
+0 (+0%)
At Close: Dec 19, 2023
Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2026
07:30am, Thursday, 16'th Apr 2026
Highlights include pooled safety findings from Paratek's Phase 3 studies in community acquired pneumonia (CABP) and acute bacterial skin and skin structure infection (ABSSSI), as well as additional cl
Paratek Pharmaceuticals Completes Combination with Radius Health, Expanding Its Multi-Product Specialty Commercial Platform
07:00am, Wednesday, 18'th Mar 2026
Transaction adds TYMLOS ® to portfolio alongside NUZYRA ® and XHANCE ® and creates a diversified portfolio expected to generate nearly $1 billion in revenue in 2026 KING OF PRUSSIA, Pa., March 18,
KING OF PRUSSIA, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the development and commercialization of specialty therapies f
Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at IDWeek 2025 and CHEST 2025
07:30am, Friday, 17'th Oct 2025
KING OF PRUSSIA, Pa. and BOSTON, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the development and commercialization of specialty
BOSTON, May 16, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the development and commercialization of specialty therapies for specialists
Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2025
07:30am, Thursday, 10'th Apr 2025
BOSTON, April 10, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company developing specialty therapies for community care and public health challenges, today
BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing innovative medical therapies that create positive patient stories in the hospi
First randomized placebo-controlled trial in NTM abscessus Symptom-based endpoints showed favorable improvement in frequency and severity of the most common symptoms Microbiologic endpoints showed hig
-- Highlights include data from clinical, non-clinical and microbiology programs, real-world patient use and a five-year microbiologic surveillance study of NUZYRA BOSTON, Oct. 14, 2024 (GLOBE NEWSWIR
Met all Primary and Secondary Efficacy Endpoints and Was Generally Safe and Well-Tolerated Largest Clinical Data Set in Pneumonia for Any Antibiotic Approved in the Last Decade Label Update Discussion
Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023
08:00am, Thursday, 05'th Oct 2023
BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies fo
Novo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
12:31pm, Thursday, 21'st Sep 2023
Novo Holdings, the controlling shareholder in drugmaker Novo Nordisk , on Thursday said it had closed its acquisition of biopharmaceutical company Paratek Pharmaceuticals in a deal valued at $462 mill
Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.
08:58am, Thursday, 21'st Sep 2023
CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Gurnet Point Capital (“Gurnet Point”) and Novo Holdings A/S (“Novo Holdings”) announced today the completion of their acquisition of Parate
Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S
09:37am, Monday, 18'th Sep 2023
BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (“Paratek”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization o
BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of no
